Samuel T Savitz1, Ronald C Chen2,3,4, David J Sher5. 1. Department of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina. 2. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4. Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND: Decisions regarding how to treat patients who have 1 to 3 brain metastases require important tradeoffs between controlling recurrences, side effects, and costs. In this analysis, the authors compared novel treatments versus usual care to determine the incremental cost-effectiveness ratio from a payer's (Medicare) perspective. METHODS: Cost-effectiveness was evaluated using a microsimulation of a Markov model for 60 one-month cycles. The model used 4 simulated cohorts of patients aged 65 years with 1 to 3 brain metastases. The 4 cohorts had a median survival of 3, 6, 12, and 24 months to test the sensitivity of the model to different prognoses. The treatment alternatives evaluated included stereotactic radiosurgery (SRS) with 3 variants of salvage after recurrence (whole-brain radiotherapy [WBRT], hippocampal avoidance WBRT [HA-WBRT], SRS plus WBRT, and SRS plus HA-WBRT). The findings were tested for robustness using probabilistic and deterministic sensitivity analyses. RESULTS: Traditional radiation therapies remained cost-effective for patients in the 3-month and 6-month cohorts. In the cohorts with longer median survival, HA-WBRT and SRS plus HA-WBRT became cost-effective relative to traditional treatments. When the treatments that involved HA-WBRT were excluded, either SRS alone or SRS plus WBRT was cost-effective relative to WBRT alone. The deterministic and probabilistic sensitivity analyses confirmed the robustness of these results. CONCLUSIONS: HA-WBRT and SRS plus HA-WBRT were cost-effective for 2 of the 4 cohorts, demonstrating the value of controlling late brain toxicity with this novel therapy. Cost-effectiveness depended on patient life expectancy. SRS was cost-effective in the cohorts with short prognoses (3 and 6 months), whereas HA-WBRT and SRS plus HA-WBRT were cost-effective in the cohorts with longer prognoses (12 and 24 months).
BACKGROUND: Decisions regarding how to treat patients who have 1 to 3 brain metastases require important tradeoffs between controlling recurrences, side effects, and costs. In this analysis, the authors compared novel treatments versus usual care to determine the incremental cost-effectiveness ratio from a payer's (Medicare) perspective. METHODS: Cost-effectiveness was evaluated using a microsimulation of a Markov model for 60 one-month cycles. The model used 4 simulated cohorts of patients aged 65 years with 1 to 3 brain metastases. The 4 cohorts had a median survival of 3, 6, 12, and 24 months to test the sensitivity of the model to different prognoses. The treatment alternatives evaluated included stereotactic radiosurgery (SRS) with 3 variants of salvage after recurrence (whole-brain radiotherapy [WBRT], hippocampal avoidance WBRT [HA-WBRT], SRS plus WBRT, and SRS plus HA-WBRT). The findings were tested for robustness using probabilistic and deterministic sensitivity analyses. RESULTS: Traditional radiation therapies remained cost-effective for patients in the 3-month and 6-month cohorts. In the cohorts with longer median survival, HA-WBRT and SRS plus HA-WBRT became cost-effective relative to traditional treatments. When the treatments that involved HA-WBRT were excluded, either SRS alone or SRS plus WBRT was cost-effective relative to WBRT alone. The deterministic and probabilistic sensitivity analyses confirmed the robustness of these results. CONCLUSIONS: HA-WBRT and SRS plus HA-WBRT were cost-effective for 2 of the 4 cohorts, demonstrating the value of controlling late brain toxicity with this novel therapy. Cost-effectiveness depended on patient life expectancy. SRS was cost-effective in the cohorts with short prognoses (3 and 6 months), whereas HA-WBRT and SRS plus HA-WBRT were cost-effective in the cohorts with longer prognoses (12 and 24 months).
Authors: Rachel F Shenker; Emory R McTyre; Glen B Taksler; Ralph B D'Agostino; Christina K Cramer; Jimmy Ruiz; Natalie K Alphonse-Sullivan; Michael Farris; Kounosuke Watabe; Fei Xing; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Clin Neurol Neurosurg Date: 2018-11-13 Impact factor: 1.876
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Syed M Adil; Sarah E Hodges; Ryan M Edwards; Lefko T Charalambous; Zidanyue Yang; Musa Kiyani; Alexis Musick; Beth A Parente; Hui-Jie Lee; Katherine B Peters; Peter E Fecci; Shivanand P Lad Journal: Neurooncol Pract Date: 2020-07-21
Authors: Michael H Soike; Jennifer Logue; Shadi Qasem; Ryan T Hughes; Emory McTyre; Jing Su; Pierre Triozzi; Maurizio Bendandi; Hui-Wen Lo; Tamjeed Ahmed; Stacey S O'Neill; Waldemar Debinski; Boris Pasche; Kounosuke Watabe; Lance D Miller; Michael D Chan; Jimmy Ruiz Journal: Sci Rep Date: 2019-10-07 Impact factor: 4.379
Authors: Michael H Soike; Emory R McTyre; Ryan T Hughes; Michael Farris; Christina K Cramer; Michael C LeCompte; Claire M Lanier; Jimmy Ruiz; Jing Su; Kounosuke Watabe; J Daniel Bourland; Michael T Munley; Stacey O'Neill; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2018-05-08 Impact factor: 4.130
Authors: Michael H Soike; Ryan T Hughes; Michael Farris; Emory R McTyre; Christina K Cramer; J D Bourland; Michael D Chan Journal: Neurosurgery Date: 2019-03-01 Impact factor: 5.315
Authors: Dirk Rades; Stefan Janssen; Amira Bajrovic; Mai Trong Khoa; Theo Veninga; Steven E Schild Journal: Radiat Oncol Date: 2017-04-24 Impact factor: 3.481
Authors: David Roberge; Paul D Brown; Anthony Whitton; Chris O'Callaghan; Anne Leis; Jeffrey Greenspoon; Grace Li Smith; Jennifer J Hu; Alan Nichol; Chad Winch; Michael D Chan Journal: Front Oncol Date: 2018-09-13 Impact factor: 6.244